We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Certain Protein Ectodomains in Cerebrospinal Fluid Are Diagnostic Biomarkers for Autism

By LabMedica International staff writers
Posted on 27 Dec 2021
Abnormally low levels of a protein biomarker, which can be detected in the cerebrospinal fluid (CSF), have the potential to be the basis for diagnosis of autism and related neurological disorders.

Mutations in the contactin-associated protein-like 2 (CNTNAP2) gene had been related to autism combined with epilepsy. More...
Autism, which has a highly genetic component, affects about 17% of children in the United States, and from 30% to 50% of these children also have epilepsy. The CNTNAP2 gene encompasses almost 1.6% of chromosome seven and is one of the largest genes in the human genome. It has been associated with autism spectrum disorder but accounts for very few cases.

Investigators at Northwestern University (Chicago, Illinois, USA) recently reported that the ectodomain (the portion of the protein extending beyond the cell membrane) of CNTNAP2 (CNTNAP2-ecto), was a prominent neurodevelopmental disorder (NDD) risk factor. As such, CNTNAP2-ecto was determined to be an important constituent of the population of brain proteins shed into the CSF, also known as the neuronal sheddome.

Transmembrane proteins sometime undergo ectodomain shedding upon proteolytic cleavage, but only a few such cases have been studied. Using unbiased global proteomic approaches, the investigators discovered that a large number of neuronal membrane proteins undergo ectodomain shedding. This “sheddome” was detectable in the cerebrospinal fluid and was enriched in synaptic proteins and disease risk factors. Unexpectedly, such ectodomains were found to have novel biological functions in regulating cellular and network level properties of brain circuits.

In the current study, the investigators found that CNTNAP2-ecto levels were reduced in the CSF of individuals with autism spectrum disorder. Using mass spectrometry, the investigators identified the plasma membrane Ca2+ ATPase (PMCA) extrusion pumps as novel CNTNAP2-ecto binding partners. CNTNAP2-ecto enhanced the activity of PMCA2 and regulated neuronal network dynamics in a PMCA2-dependent manner.

“We can replace CNTNAP2,” said senior author Dr. Peter Penzes, professor of psychiatry and behavioral sciences at Northwestern University. “We can make it in a test tube and should be able inject it into children’s spinal fluid, which will go back into their brain.”

The study was published in the December 17, 2021 online edition of the journal Neuron.

Related Links:
Northwestern University


Gold Member
Blood Gas Analyzer
Stat Profile pHOx
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Sample Transportation System
Tempus1800 Necto
HBV DNA Test
GENERIC HBV VIRAL LOAD VER 2.0
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Whole-genome sequencing enables broader detection of DNA repair defects to guide PARP inhibitor cancer therapy (Photo courtesy of Illumina)

Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment

Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.